Drug Profile


Alternative Names: CP 66248; CP 66248 2; Enable; Enablex® - Rheumatoid arthritis; Kenida®; Reumaten; Tenedac

Latest Information Update: 25 Mar 1998

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Pfizer; Roerig
  • Class Anti-inflammatories; Antirheumatics; Indoles
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections; Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 25 Mar 1998 Discontinued-Preregistration for Osteoarthritis in USA (PO)
  • 30 Jan 1998 Discontinued-I for HIV infections treatment in USA (Unknown route)
  • 05 Dec 1997 Data have been added to the Therapeutic Trials and Adverse Events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top